Meyka Pro banner
Novocure Ltd

Novocure Ltd Fundamental Analysis (NASDAQ: NVCR)

NVCR●NASDAQ
HealthcareMedical - Devices
$12.53
$0.75(5.65%)
U.S. Market opens in 15h 49m

Novocure Ltd Fundamental Analysis (NASDAQ: NVCR)

Novocure Ltd (NASDAQ: NVCR) shows moderate financial fundamentals with a PE ratio of -12.48, profit margin of -16.78%, and ROE of -35.81%. The company generates $0.7B in annual revenue with moderate year-over-year growth of 8.28%.

Key Strengths

Cash Position31.72%
PEG Ratio-0.48
Current Ratio2.49

Areas of Concern

ROE-35.81%
Operating Margin-17.17%
We analyze NVCR's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -17.0/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-17.0/100

We analyze NVCR's fundamental strength across five key dimensions:

Efficiency Score

Weak

NVCR struggles to generate sufficient returns from assets.

ROA > 10%
-14.69%

Valuation Score

Excellent

NVCR trades at attractive valuation levels.

PE < 25
-12.48
PEG Ratio < 2
-0.48

Growth Score

Excellent

NVCR delivers strong and consistent growth momentum.

Revenue Growth > 5%
8.28%
EPS Growth > 10%
21.79%

Financial Health Score

Excellent

NVCR maintains a strong and stable balance sheet.

Debt/Equity < 1
0.66
Current Ratio > 1
2.49

Profitability Score

Weak

NVCR struggles to sustain strong margins.

ROE > 15%
-3580.59%
Net Margin ≥ 15%
-16.78%
Positive Free Cash Flow
No

Key Financial Metrics

Is NVCR Expensive or Cheap?

P/E Ratio

NVCR trades at -12.48 times earnings. This suggests potential undervaluation.

-12.48

PEG Ratio

When adjusting for growth, NVCR's PEG of -0.48 indicates potential undervaluation.

-0.48

Price to Book

The market values Novocure Ltd at 4.41 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.41

EV/EBITDA

Enterprise value stands at -13.55 times EBITDA. This is generally considered low.

-13.55

How Well Does NVCR Make Money?

Net Profit Margin

For every $100 in sales, Novocure Ltd keeps $-16.78 as profit after all expenses.

-16.78%

Operating Margin

Core operations generate -17.17 in profit for every $100 in revenue, before interest and taxes.

-17.17%

ROE

Management delivers $-35.81 in profit for every $100 of shareholder equity.

-35.81%

ROA

Novocure Ltd generates $-14.69 in profit for every $100 in assets, demonstrating efficient asset deployment.

-14.69%

Following the Money - Real Cash Generation

Operating Cash Flow

Novocure Ltd generates limited operating cash flow of $3.59M, signaling weaker underlying cash strength.

$3.59M

Free Cash Flow

Novocure Ltd generates weak or negative free cash flow of $-20.32M, restricting financial flexibility.

$-20.32M

FCF Per Share

Each share generates $-0.17 in free cash annually.

$-0.17

FCF Yield

NVCR converts -1.31% of its market value into free cash.

-1.31%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-12.48

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.48

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.41

vs 25 benchmark

P/S Ratio

Price to sales ratio

2.13

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.66

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.49

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.36

vs 25 benchmark

ROA

Return on assets percentage

-0.15

vs 25 benchmark

ROCE

Return on capital employed

-0.22

vs 25 benchmark

How NVCR Stacks Against Its Sector Peers

MetricNVCR ValueSector AveragePerformance
P/E Ratio-12.4830.84 Better (Cheaper)
ROE-35.81%573.00% Weak
Net Margin-16.78%5349.00% Weak
Debt/Equity0.66-0.03 (disorted) Distorted
Current Ratio2.495.76 Strong Liquidity
ROA-14.69%-254.00% (disorted) Weak

NVCR outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Novocure Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

20.03%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-722.70%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-144.78%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ